Processes for the preparation of aryl-and heteroaryl-alkylsulfonyl halides
申请人:Michalak S. Ronald
公开号:US20050187408A1
公开(公告)日:2005-08-25
The present invention provides processes for the preparation of arylalkylsulfonyl halides and heteroarylalkylsufonyl halides of Formula I: Ar—R—SO
2
—X, that are useful as intermediates in the preparation of pharmaceuticals.
This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A
2
enzymes (cPLA
2
), more particularly including inhibitors of cytosolic phospholipase A
2
alpha enzymes (cPLA
2
α). In some embodiments, the inhibitors have the Formula I:
wherein the constituent variables are as defined herein.
This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A
2
enzymes (cPLA
2
), more particularly including inhibitors of cytosolic phospholipase A
2
alpha enzymes (cPLA
2
α). In some embodiments, the inhibitors have the Formula I:
wherein the constituent variables are as defined herein.
Processes for the preparation of aryl- and heteroaryl-alkylsulfonyl halides
申请人:Wyeth
公开号:US07321061B2
公开(公告)日:2008-01-22
The present invention provides processes for the preparation of arylalkylsulfonyl halides and heteroarylalkylsufonyl halides of Formula I: Ar—R—SO2—X, that are useful as intermediates in the preparation of pharmaceuticals.
This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2). Of particular interest is 4-(3-5-chloro-1-(diphenylmethyl)-2-[2-([2-(trifluoromethyl)benzy]sulfonyl}amino)ethyl]-1H-indol-3-yl}propyl) benzoic acid, or a pharmaceutically acceptable salt thereof. The compounds of the invention are indicated, inter alia, in the treatment of inflammation.